Oxford, UK – 13 October 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene and cell therapy company, announces that it has acquired the freehold of the Windrush Court office and laboratory facilities in Transport Way, Oxford, England, for a total cash consideration of £3.2 million from Oxford Real Estate Owner No. 2 Limited.
Windrush Court, a 6,684 sq m facility, is located directly opposite Oxford BioMedica’s manufacturing facility and the Company intends to relocate its laboratories and office activities there in stages before the current lease of the Medawar Centre, Oxford expires in March 2016. The purchase of Windrush Court will enable the Company to consolidate its entire activities in Transport Way, improving operational effectiveness, and will also provide additional capacity to accommodate the planned growth in business activities. As a result of the expected savings in rental costs and service charges, Oxford BioMedica expects to recover the purchase cost within 4 years.
Notes to editors
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications – Media Enquiries
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton/Rosie Phillips
Tel: +44 (0)20 3709 5700